<DOC>
	<DOCNO>NCT00742508</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability SK &amp; F-105517-D japanese patient chronic heart failure .</brief_summary>
	<brief_title>A Phase I/II Clinical Study SK &amp; F-105517-D Japanese Patients With Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Inclusion criterion : Patients symptomatically stable chronic heart failure ( CHF ) base ischemic heart disease dilate cardiomyopathy Patients maintain basic heart failure therapy angiotensin convert enzyme ( ACE ) inhibitor angiotensin II receptor blocker ( ARB ) dosage/administration change within 2 week Patients diagnose New York Heart Association ( NYHA ) class I III Patients leave ventricular ejection fraction ( LVEF ) 25 % 45 % Patients contraindicated ßblockers Patients occurrence acute myocardial infarction within 2 week Patients unstable angina , coronary spastic angina , angina rest Patients collect blood &gt; 400 mL within 4 month prior screen &gt; 200 mL within 1 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>carvedilol phosphate</keyword>
	<keyword>ß-blocker</keyword>
	<keyword>SK &amp; F-105517-D</keyword>
	<keyword>Chronic heart failure ( CHF )</keyword>
</DOC>